Next-Generation Anticoagulants: Precision Strategies for Patient-Centered Thromboprophylaxis
Journal of Personalized Medicine · 14.10.2025 · 15 (10) · 490
DOI: 10.3390/jpm15100490 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 14.10.2025. Verfasst von Abdulrahman Nasiri und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), 11623 Riyadh, Saudi Arabia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Thrombosis remains a leading preventable cause of global morbidity and mortality, with conditions like venous thromboembolism and atrial fibrillation affecting millions worldwide. Traditional anticoagulants (heparins, vitamin K antagonists) require careful monitoring due to narrow therapeutic windows. Direct oral anticoagulants (DOACs) greatly improved convenience and reduced certain hemorrhagic complications (notably intracranial hemorrhage) compared to warfarin, but bleeding, drug–drug interactions, and unmet needs in special populations persist. This review highlights emerging strategies to decouple antithrombotic efficacy from bleeding risk. Novel agents targeting factor XI or XII (small molecules, antibodies, antisense oligonucleotides) have shown in early trials robust thromboembolism prevention with low bleeding. Advances in pharmacogenomics, biomarker-guided dosing, artificial intelligence risk prediction, and digital monitoring promise to personalize therapy. We discuss optimized approaches for high-risk subgroups (cancer-associated thrombosis, extremes of body weight, renal/hepatic dysfunction, pregnancy, perioperative care, and COVID-19) with citations to current evidence. Finally, we outline critical systems-level considerations, including drug accessibility, cost-effectiveness, and educational strategies, that are necessary to realize precision anticoagulation. Our synthesis is grounded in recent peer-reviewed literature and emphasizes innovations likely to improve safety and efficacy of thromboprophylaxis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), 11623 Riyadh, Saudi Arabia.
- Department of Hematology, Oncology Center, King Salman Specialist Hospital, 55741 Hail, Saudi Arabia.
- Pharmacy Department, Security Forces Hospitals Program, General Directorate of Medical Services, Ministry of Interior, 11481 Riyadh, Saudi Arabia.
- Department of Medical Oncology and Haematology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
- Internal Medicine Department, Security Forces Hospitals Program, General Directorate of Medical Services, Ministry of Interior, 11481 Riyadh, Saudi Arabia.
ORCID-Profile: Abdulrahman Nasiri
Zitieren
APA
Nasiri, A., Alshammari, M., Alqahtani, R., Alshaer, O., Alsolamy, E., Alghethber, H., & Alkharras, R. (2025). Next-Generation Anticoagulants: Precision Strategies for Patient-Centered Thromboprophylaxis. Journal of Personalized Medicine, 15(10), 490. https://doi.org/10.3390/jpm15100490
Vancouver
Nasiri A, Alshammari M, Alqahtani R, Alshaer O, Alsolamy E, Alghethber H, et al. Next-Generation Anticoagulants: Precision Strategies for Patient-Centered Thromboprophylaxis. Journal of Personalized Medicine. 2025;15(10):490. doi:10.3390/jpm15100490
BibTeX
@article{Nasiri2025,
author = {Nasiri, Abdulrahman and Alshammari, Manal and Alqahtani, Rawan and Alshaer, Omar and Alsolamy, Eysa and Alghethber, Hamad and Alkharras, Reem},
title = {Next-Generation Anticoagulants: Precision Strategies for Patient-Centered Thromboprophylaxis},
journal = {Journal of Personalized Medicine},
year = {2025},
volume = {15},
number = {10},
pages = {490},
doi = {10.3390/jpm15100490}
}
EUVIMED